Chromadex Corp Stock Price, News & Analysis

ChromaDex Corp. (NASDAQ: CDXC) has announced a securities purchase agreement for a private placement of $25 million in common stock. The placement involves selling 3,846,153 shares at $6.50 each, led by a new international investor, with expected closure by February 23, 2021. The funds will enhance the growth of its flagship product, Tru Niagen^®, and support clinical research on NAD⁺ precursors. ChromaDex will enter a registration rights agreement and assures these shares are not registered under the Securities Act of 1933.

ChromaDex Corp. (NASDAQ:CDXC) will host a conference call on March 10, 2021, at 4:30 p.m. ET to discuss its fourth-quarter financial results for the period ending December 31, 2020. The results will be announced in a press release after market close. Interested participants should dial in 10 minutes prior. The toll-free and international numbers are provided in the announcement. A replay of the call will be available post-event. ChromaDex focuses on nutraceuticals and is known for its NIAGEN® ingredient, aimed at improving health as people age.

ChromaDex Corp. (NASDAQ: CDXC) announced positive results from a Phase 2 study on the effects of a nutritional protocol involving nicotinamide riboside (NR) on non-alcoholic fatty liver disease (NAFLD). The study demonstrated a significant 10% reduction in liver fat and 39% decrease in serum ALT levels among 31 overweight or obese participants. Conducted with the ChromaDex External Research Program, the findings suggest that metabolic cofactor supplementation may enhance liver health. ChromaDex has invested over $35 million in NR research and holds more than 20 patents related to its use.

ChromaDex Corp. (NASDAQ: CDXC) will present at the Benzinga Small Cap Conference on December 9, 2020, at 11:15 AM ET. This virtual event aims to connect small-cap companies with investors and traders, featuring networking and educational opportunities. ChromaDex will have a presentation available for replay on its investor relations website following the event. The company specializes in nutraceuticals, focusing on improving aging through its flagship ingredient, NIAGEN®.

ChromaDex Corp. (NASDAQ:CDXC) has launched a clinical trial at the University of California, Davis, investigating the effects of Niagen® (nicotinamide riboside) on milk production in preterm mothers. Following positive preclinical results, the double-blinded study will assess milk production and metabolic markers among 32 participants over 14 days. Previously, NR supplementation increased milk production in rodent studies, with potential benefits for both mothers and their newborns. ChromaDex has invested over $35 million in Niagen research and marketing, aimed at exploring its health benefits.

ChromaDex Corp. (NASDAQ:CDXC) has launched its exclusive TRU NIAGEN® EX Stick Packs in collaboration with Watsons Hong Kong, available both online and in stores. TRU NIAGEN® has been the best-selling supplement at Watsons, and the new stick packs provide an alternative delivery method for this healthy aging vitamin. Each pack contains 300mg of nicotinamide riboside, aiming to appeal to fitness-focused consumers. The partnership, ongoing since 2017, broadens the product's accessibility to health-conscious customers.

ChromaDex (Nasdaq: CDXC) reported Q3 2020 net sales of $14.2 million, an 18% increase from the previous year. Tru Niagen® sales reached $11.9 million, up 22%. The net loss improved to ($4.2) million or ($0.07) per share, compared to ($7.2) million in Q3 2019. Adjusted EBITDA loss was ($0.1) million, a $1.7 million improvement year-over-year. The company anticipates continued revenue growth from its e-commerce and international markets, alongside improved gross margins.

ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on November 4, 2020, at 4:30 p.m. ET to discuss its financial results for Q3 2020, ending September 30. This call will follow the release of their earnings report, which will be shared after market close on the same day. Investors wishing to participate should dial in 10 minutes early. A replay will be available post-call. ChromaDex is focused on developing nutraceuticals, notably its flagship ingredient, NIAGEN®, aimed at enhancing human health.

ChromaDex Corp. (NASDAQ:CDXC) has highlighted a groundbreaking study published in The European Molecular Biology Organization Journal on nicotinamide riboside (NR) and its role in maintaining telomeres, critical for DNA integrity. Conducted by the National Institute on Aging and the National Cancer Institute, this study shows NR's potential in raising NAD⁺ levels, protecting telomeres, and possibly aiding in the fight against age-related diseases. ChromaDex provided NR via its External Research Program, while the study underscores the need for further research into NR's benefits.